| Incorporation By Reference | ||||||||||
| Exhibit Number | Description of Document | Form | SEC File No. | Exhibit | Filing Date | |||||
| 2.1#† | Asset Purchase Agreement, dated as of August 13, 2018, by and between Escape Therapeutics, Inc. and AgeX Therapeutics, Inc. | 10-12(b) A-2 | 001-38519 | 2.1 | 8/30/2018 | |||||
| 2.2† | Agreement and Plan of Merger and Reorganization, dated August 29, 2023, by and among AgeX Therapeutics, Inc., Canaria Transaction Corporation and Serina Therapeutics, Inc. | 8-K | 001-38519 | 2.1 | 8/30/2023 | |||||
| 3.1 | Amended and Restated Certificate of Incorporation of Serina Therapeutics, Inc. | 8-K | 001-38519 | 3.1 | 4/1/2024 | |||||
| 3.2 | Amended and Restated Bylaws of Serina Therapeutics, Inc. | 8-K | 001-38519 | 3.2 | 4/1/2024 | |||||
| 4.1 | Form of Warrant included in Warrant Agreement dated March 30, 2020. | 10-K | 001-38519 | 10.25 | 3/30/2020 | |||||
| 4.2 | Form of Warrant included in Warrant Agreement dated February 14, 2022. | 8-K | 001-38519 | 2/15/2022 | ||||||
| 4.3 | Form of Post-Merger Warrant included in Warrant Agreement dated March 19, 2024. | 10-K | 001-38519 | 4.4 | 3/22/2024 | |||||
| 4.4 | Form of Incentive Warrant included in Warrant Agreement dated March 19, 2024. | 10-K | 001-38519 | 4.5 | 3/22/2024 | |||||
| 5.1* | Opinion of Bradley Arant Boult Cummings LLP | |||||||||
| 10.1# | Asset Contribution and Separation Agreement dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc. | 10-Q | 001-12830 | 10.1 | 11/9/2017 | |||||
| Incorporation By Reference | ||||||||||
| Exhibit Number | Description of Document | Form | SEC File No. | Exhibit | Filing Date | |||||
| 2.1#† | Asset Purchase Agreement, dated as of August 13, 2018, by and between Escape Therapeutics, Inc. and AgeX Therapeutics, Inc. | 10-12(b) A-2 | 001-38519 | 2.1 | 8/30/2018 | |||||
| 2.2† | Agreement and Plan of Merger and Reorganization, dated August 29, 2023, by and among AgeX Therapeutics, Inc., Canaria Transaction Corporation and Serina Therapeutics, Inc. | 8-K | 001-38519 | 2.1 | 8/30/2023 | |||||
| 3.1 | Amended and Restated Certificate of Incorporation of Serina Therapeutics, Inc. | 8-K | 001-38519 | 3.1 | 4/1/2024 | |||||
| 3.2 | Amended and Restated Bylaws of Serina Therapeutics, Inc. | 8-K | 001-38519 | 3.2 | 4/1/2024 | |||||
| 4.1 | Form of Warrant included in Warrant Agreement dated March 30, 2020. | 10-K | 001-38519 | 10.25 | 3/30/2020 | |||||
| 4.2 | Form of Warrant included in Warrant Agreement dated February 14, 2022. | 8-K | 001-38519 | 2/15/2022 | ||||||
| 4.3 | Form of Post-Merger Warrant included in Warrant Agreement dated March 19, 2024. | 10-K | 001-38519 | 4.4 | 3/22/2024 | |||||
| 4.4 | Form of Incentive Warrant included in Warrant Agreement dated March 19, 2024. | 10-K | 001-38519 | 4.5 | 3/22/2024 | |||||
| 5.1* | Opinion of Bradley Arant Boult Cummings LLP | |||||||||
| 10.1# | Asset Contribution and Separation Agreement dated August 17, 2017, between Lineage Cell Therapeutics, Inc. and AgeX Therapeutics, Inc. | 10-Q | 001-12830 | 10.1 | 11/9/2017 | |||||
